After Shinya Yamanaka, Ph.D. won the Nobel Prize in 2012 for his work with induced pluripotent stem cells, the discovery race for stem cell advancement spread around the world. As break-throughs in the lab led to first-in-human trials for stem cells, our Founder, Pete O’Heeron recognized the potential therapeutic benefits of fibroblasts and began to develop the science around this “new” cell source. Fibroblasts, one of the most abundant cells in the human body and present in all tissues and systems, have demonstrated similar characteristics as stem cells, but appear to be a better cell source due to their potency and ease of use1, 2.
Challenging our scientists to explore the “edge of the envelope” for clinical applications, we discovered that fibroblasts seem to be involved in many of the body’s biological processes. The potential curative benefits of fibroblasts seem almost endless and our company is dedicated to achieving cures for chronic diseases and regenerative medicine using this unique, potent and abundant cell source.